1 reports of this reaction
16.7% of all ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL reports
#2 most reported adverse reaction
CARDIO RESPIRATORY ARREST is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL, manufactured by Wal-Mart Stores Inc. There are 1 FDA adverse event reports linking ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL to CARDIO RESPIRATORY ARREST. This represents approximately 16.7% of all 6 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL who experience cardio respiratory arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIO RESPIRATORY ARREST is a frequently reported adverse event for ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL, accounting for a significant proportion of all reports.
In addition to cardio respiratory arrest, the following adverse reactions have been reported for ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL:
The following drugs have also been linked to cardio respiratory arrest in FDA adverse event reports:
CARDIO RESPIRATORY ARREST has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIO RESPIRATORY ARREST accounts for approximately 16.7% of all adverse event reports for ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL, making it one of the most commonly reported side effect.
If you experience cardio respiratory arrest while taking ACETAMINOPHEN, GUAIFENESIN, PHENYLEPHRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.